» Articles » PMID: 32017704

Amyloid-β, Tau, and the Cholinergic System in Alzheimer's Disease: Seeking Direction in a Tangle of Clues

Overview
Journal Rev Neurosci
Publisher De Gruyter
Specialty Neurology
Date 2020 Feb 5
PMID 32017704
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The link between histopathological hallmarks of Alzheimer's disease (AD), i.e. amyloid plaques, and neurofibrillary tangles, and AD-associated cognitive impairment, has long been established. However, the introduction of interactions between amyloid-beta (Aβ) as well as hyperphosphorylated tau, and the cholinergic system to the territory of descriptive neuropathology has drastically changed this field by adding the theory of synaptic neurotransmission to the toxic pas de deux in AD. Accumulating data show that a multitarget approach involving all amyloid, tau, and cholinergic hypotheses could better explain the evolution of events happening in AD. Various species of both Aβ and tau could be traced in cholinergic neurons of the basal forebrain system early in the course of the disease. These molecules induce degeneration in the neurons of this system. Reciprocally, aberrant cholinergic system modulation promotes changes in amyloid precursor protein (APP) metabolism and tau phosphorylation, resulting in neurotoxicity, neuroinflammation, and neuronal death. Altogether, these changes may better correlate with the clinical findings and cognitive impairment detected in AD patients. Failure of several of Aβ- and tau-related therapies further highlights the need for special attention to molecules that target all of these mentioned pathologic changes. Another noteworthy fact here is that none of the popular hypotheses of AD such as amyloidopathy or tauopathy seem to be responsible for the changes observed in AD alone. Thus, the main culprit should be sought higher in the stream somewhere in APP metabolism or Wnt signaling in the cholinergic system of the basal forebrain. Future studies should target these pathological events.

Citing Articles

Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.

Reddi Sree R, Kalyan M, Anand N, Mani S, Gorantla V, Sakharkar M ACS Omega. 2025; 10(6):5148-5171.

PMID: 39989768 PMC: 11840625. DOI: 10.1021/acsomega.4c05527.


Recent Advances in the Search for Effective Anti-Alzheimer's Drugs.

Ogos M, Stary D, Bajda M Int J Mol Sci. 2025; 26(1.

PMID: 39796014 PMC: 11720639. DOI: 10.3390/ijms26010157.


Dexmedetomidine Improves Learning Functions in Male Rats Modeling Cognitive Impairment by Modulating the BDNF/TrkB/CREB Signaling Pathway.

Saral S, Mercantepe T, Topcu A, Kaya A, Ozturk A Life (Basel). 2025; 14(12.

PMID: 39768379 PMC: 11728090. DOI: 10.3390/life14121672.


Alzheimer's Disease, Obesity, and Type 2 Diabetes: Focus on Common Neuroglial Dysfunctions (Critical Review and New Data on Human Brain and Models).

Toledano A, Rodriguez-Casado A, Alvarez M, Toledano-Diaz A Brain Sci. 2024; 14(11).

PMID: 39595866 PMC: 11591712. DOI: 10.3390/brainsci14111101.


Mannich reaction mediated derivatization of chromones and their biological evaluations as putative multipotent ligands for the treatment of Alzheimer's disease.

Kumar N, Jangid K, Kumar V, Devi B, Arora T, Mishra J RSC Med Chem. 2024; .

PMID: 39399311 PMC: 11462584. DOI: 10.1039/d4md00550c.